【摘要】 目的探究瑞舒伐他汀与阿托伐他汀强化降脂治疗对急性脑梗死患者血脂水平、血管内皮生长因子(VEGF)及同型半胱氨酸(Hcy)水平的影响。方法将120例急性脑梗死患者分为A组(睡前口服20 mg瑞舒伐他汀)和B组(睡前口服60 mg阿托伐他汀)各60例。比较两组治疗前后血脂、炎症因子、VEGF、Hcy水平及美国国立卫生院卒中评分(NIHSS)、改良Rankin评分(mRS),并对比两组治疗安全性。结果 A组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白-胆固醇(LDL-C)水平均低于B组(P<0.05);治疗后A组炎症因子水平、Hcy水平及NIHSS评分、mRS评分均低于B组,VEGF水平高于B组(P<0.05)。结论与阿托伐他汀比较,瑞舒伐他汀强化降脂治疗对急性脑梗死患者的降脂效果及抗炎效果更为明显,且瑞舒伐他汀或可通过提高VEGF水平,降低Hcy水平起到一定神经保护作用,减轻血管内皮功能损伤,抑制血栓形成。更多还原

【Abstract】 Objective To investigate the effects of rosuvastatin and atorvastatin intensive lipid-lowering therapy on levels of blood lipids,vascular endothelial growth factor(VEGF) and homocysteine(Hey) in patients with acute cerebral infarction(ACI).Methods One hundred and twenty patients with ACI admitted to our hospital were divided into the group A(20 mg rosuvastatin orally before bed) and group B(60 mg atorvastatin orally before bedtime),60 in each group.The levels of blood lipids,inflammatory factors,VEGF and Hey,scores of National Institutes of Health Stroke Scale(NIHSS) and modified Rankin scale(mRS) before and after treatment were compared between the two groups.Meanwhile,the safety was also compared between the two groups.Results The levels of total cholesterol(TC),triglyceride(TG) and low density lipoprotein-cholesterol(LDL-C) in the group A were lower than those in the group B(P <0.05).The levels of inflammatory factors and Hey,NIHSS score and mRS score of the group A after treatment were significantly lower than those in the group B,and the level of VEGF was significantly higher than B group(P <0.05).Conclusion Compared with atorvastatin,rosuvastatin intensive lipid-lowering therapy is more effective in terms of lipid lowering and anti-inflammatory effect in patients with ACI.Besides,rosuvastatin can protect the nerves to a certain degree by increasing VEGF levels and reducing Hey levels.It also can relieve endothelial dysfunction and inhibit thrombosis.更多还原